Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide.
Thalidomide is effective in the treatment of multiple myeloma. The immunomodulatory drug and thalidomide analogue lenalidomide is currently in late stage clinical development for MDS and multiple myeloma. This minireview highlights the course of initial and ongoing lenalidomide clinical development in oncology with reference to earlier thalidomide studies.
Bartlett
J B
JB
Celgene Corporation, 86 Morris Avenue, Summit, NJ 07901, USA. bbartlett@celgene.com
Tozer
A
A
Stirling
D
D
Zeldis
J B
JB
D002986:Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy*; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000276:immunology; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D013792:Thalidomide; D000077269:Lenalidomide